{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:58Z","timestamp":1793137018931,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.repc.2019.03.008","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:33:39Z","timestamp":1585676019000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novas perspetivas no tratamento farmacol\u00f3gico da miocardiopatia hipertr\u00f3fica"],"prefix":"10.1016","volume":"39","author":[{"given":"S\u00e9rgio","family":"Malt\u00eas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Rocha","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2019.03.008_bib0335","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.03.008_bib0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classi\ufb01cation of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2019.03.008_bib0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0350","doi-asserted-by":"crossref","unstructured":"Force T, Bonow RO, Houser SR et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. S2010;122:1130\u20103.","DOI":"10.1161\/CIRCULATIONAHA.110.950089"},{"key":"10.1016\/j.repc.2019.03.008_bib0355","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2019.03.008_bib0360","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.repc.2019.03.008_bib0365","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2019.03.008_bib0370","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2019.03.008_bib0375","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"31","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0380","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/hrt.2005.068577","article-title":"Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart."},{"key":"10.1016\/j.repc.2019.03.008_bib0385","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/hc0402.102990","article-title":"Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly","volume":"105","author":"Niimura","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0390","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/CIRCRESAHA.111.242974","article-title":"Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy","volume":"109","author":"Ashrafian","year":"2011","journal-title":"Circulation Research."},{"key":"10.1016\/j.repc.2019.03.008_bib0395","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4330\/wjc.v6.i2.26","article-title":"Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives","volume":"6","author":"Efthimiadis","year":"2014","journal-title":"World J Cardiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0400","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","article-title":"Targets for therapy in sarcomeric cardiomyopathies","volume":"105","author":"Tardiff","year":"2015","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.repc.2019.03.008_bib0405","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1172\/JCI11093","article-title":"An abnormal Ca(2+) response in mutant sarcomere protein\u2010mediated familial hypertrophic cardiomyopathy","volume":"106","author":"Fatkin","year":"2000","journal-title":"J Clin Invest. Dez"},{"key":"10.1016\/j.repc.2019.03.008_bib0410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","article-title":"Diltiazem treatment for pre\u2010clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression","volume":"3","author":"Ho","year":"2015","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.repc.2019.03.008_bib0415","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1172\/JCI200214677","article-title":"The L\u2010type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model","volume":"109","author":"Semsarian","year":"2002","journal-title":"J Clin Invest."},{"key":"10.1016\/j.repc.2019.03.008_bib0420","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.repc.2019.03.008_bib0425","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejheart.2005.07.012","article-title":"Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy","volume":"8","author":"Westermann","year":"2006","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2019.03.008_bib0430","first-page":"222","article-title":"Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment","volume":"2013","author":"Coppini","year":"2013","journal-title":"Glob Cardiol Sci Pract."},{"key":"10.1016\/j.repc.2019.03.008_bib0435","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0440","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE\u2010HCM Randomized, Double\u2010Blind","volume":"11","author":"Olivotto","year":"2018","journal-title":"Placebo\u2010Controlled Study. Circ Heart Fail."},{"key":"10.1016\/j.repc.2019.03.008_bib0445","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/CRD.0000000000000211","article-title":"Novel Pharmacotherapy in Hypertrophic Cardiomyopathy","volume":"26","author":"Andries","year":"2018","journal-title":"Cardiol Rev."},{"key":"10.1016\/j.repc.2019.03.008_bib0450","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1161\/CIRCULATIONAHA.110.981464","article-title":"Perhexiline and hypertrophic cardiomyopathy: A new horizon for metabolic modulation","volume":"122","author":"Horowitz","year":"2010","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0455","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-2952(96)00204-3","article-title":"Inhibition of carnitine palmitoyltransferase\u20101 in rat heart and liver by perhexiline and amiodarone","volume":"52","author":"Kennedy","year":"1996","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.repc.2019.03.008_bib0460","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(15)61283-1","article-title":"Pharmacological and emerging therapies in the treatment of chronic angina","volume":"386","author":"Husted","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2019.03.008_bib0465","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1527-3466.2007.00006.x","volume":"25","author":"Ashrafian","year":"2007","journal-title":"Perhexiline. Cardiovasc Drug Rev"},{"key":"10.1016\/j.repc.2019.03.008_bib0470","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcmg.2008.08.005","volume":"2","author":"Hudsmith","year":"2009","journal-title":"Neubauer. Magnetic Resonance Spectroscopy in Myocardial Disease. JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2019.03.008_bib0475","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2019.03.008_bib0480","first-page":"230","article-title":"Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA Cardiol","volume":"4","author":"Coats","year":"2019"},{"key":"10.1016\/j.repc.2019.03.008_bib0485","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2007.04.005","article-title":"N\u2010acetylcysteine \u2010 a safe antidote for cysteine\/glutathione deficiency","volume":"7","author":"Atkuri","year":"2007","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.repc.2019.03.008_bib0490","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501","article-title":"Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol\u2010sensitive mechanisms","volume":"119","author":"Lombardi","year":"2009","journal-title":"Circulation Mar"},{"key":"10.1016\/j.repc.2019.03.008_bib0495","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.RES.0000177090.07296.ac","article-title":"Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy","volume":"97","author":"Senthil","year":"2005","journal-title":"Circ Res."},{"key":"10.1016\/j.repc.2019.03.008_bib0500","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2019.03.008_bib0505","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2005.10.041","article-title":"Antifibrotic effects of antioxidant N\u2010acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation","volume":"47","author":"Marian","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0510","first-page":"1109","article-title":"Hypertrophy Regression With N\u2010Acetylcysteine in Hypertrophic Cardiomyopathy (HALT\u2010HCM): A Randomized, Placebo\u2010Controlled","volume":"122","author":"Marian","year":"2018","journal-title":"Double\u2010Blind Pilot Study. Circ Res."},{"key":"10.1016\/j.repc.2019.03.008_bib0515","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1365-2362.2010.02377.x","article-title":"Statin therapy for hypertrophic cardiomyopathy: too good to be true?","volume":"40","author":"Kostner","year":"2010","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.repc.2019.03.008_bib0520","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.CIR.104.3.317","article-title":"Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy","volume":"104","author":"Patel","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0525","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1016\/j.repc.2019.03.008_bib0530","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2362.2007.01837.x","article-title":"Statins: a perspective for left ventricular hypertrophy treatment","volume":"37","author":"Simko","year":"2007","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.repc.2019.03.008_bib0535","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-2362.2010.02349.x","article-title":"Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study","volume":"40","author":"Nagueh","year":"2010","journal-title":"Eur J Clin Invest. Nov"},{"key":"10.1016\/j.repc.2019.03.008_bib0540","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2362.2007.01877.x","article-title":"HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo\u2010controlled pilot study","volume":"37","author":"Bauersachs","year":"2007","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.repc.2019.03.008_bib0545","first-page":"129","article-title":"Statin Induced Regression of Cardiomyopathy Trial: A Randomized","volume":"17","author":"Hersi","year":"2016","journal-title":"Placebo\u2010controlled Double\u2010blind Trial. Heart Views."},{"key":"10.1016\/j.repc.2019.03.008_bib0550","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0555","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1470320311405247","article-title":"Impact of polymorphisms in the renin\u2013angiotensin\u2013aldosterone system on hypertrophic cardiomyopathy","volume":"12","author":"Orenes-Pi\u00f1ero","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.repc.2019.03.008_bib0560","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(99)06187-5","article-title":"Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy","volume":"355","author":"Marian","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2019.03.008_bib0565","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2019.03.008_bib0570","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.fjc.0000248236.43760.86","article-title":"Combined Effects of Low\u2010Dose Spironolactone and Captopril Therapy in a Rat Model of Genetic Hypertrophic Cardiomyopathy","volume":"48","author":"de Resende","year":"2006","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.repc.2019.03.008_bib0575","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1253\/circj.69.1244","article-title":"Valsartan Decreases Type I Collagen Synthesis in Patients With Hypertrophic Cardiomyopathy","volume":"69","author":"Kawano","year":"2005","journal-title":"Circ J."},{"key":"10.1016\/j.repc.2019.03.008_bib0580","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of Losartan on Left Ventricular Diastolic Function in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"96","author":"Araujo","year":"2005","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0585","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.48.715","article-title":"New Therapeutic Strategy for Hypertrophic Nonobstructive Cardiomyopathy in Humans A Randomized and Prospective Study With an Angiotensin II Receptor Blocker","volume":"48","author":"Yamazaki","year":"2007","journal-title":"Int Heart J. Nov"},{"key":"10.1016\/j.repc.2019.03.008_bib0590","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.repc.2019.03.008_bib0595","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy. A Pilot","volume":"11","author":"Penicka","year":"2009","journal-title":"Randomized Study. J Mol Diagn."},{"key":"10.1016\/j.repc.2019.03.008_bib0600","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double\u2010blind, placebo\u2010controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.repc.2019.03.008_bib0605","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1126\/science.aaf1636","article-title":"Throttling back the heart's molecular motor. A small molecule inhibits mutated forms of myosin that cause cardiac hypertrophy","volume":"351","author":"Warshaw","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.repc.2019.03.008_bib0610","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small\u2010molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"35","author":"Green","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.repc.2019.03.008_bib0615","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00424-013-1409-7","article-title":"MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA\u2010based correction","volume":"466","author":"Behrens-Gawlik","year":"2014","journal-title":"Pflugers Arch \u2010 Eur J Physiol."},{"key":"10.1016\/j.repc.2019.03.008_bib0620","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long\u2010term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun."},{"key":"10.1016\/j.repc.2019.03.008_bib0625","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans\u2010Splicing and Gene Replacement as Therapeutic Options in Human iPSC\u2010Derived Cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"10.1016\/j.repc.2019.03.008_bib0630","first-page":"1060","article-title":"Rescue of cardiomyopathy through U7snRNA\u2010mediated exon skipping in Mybpc3\u2010targeted knock\u2010in mice","volume":"5","author":"Hornung","year":"2013","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.repc.2019.03.008_bib0635","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tig.2011.02.004","article-title":"Genetic therapies for RNA mis\u2010splicing diseases","volume":"27","author":"Hammond","year":"2011","journal-title":"Trends Genet."},{"key":"10.1016\/j.repc.2019.03.008_bib0640","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jid.2012.101","article-title":"Spliceosome\u2010Mediated Trans\u2010Splicing: The Therapeutic Cut and Paste","volume":"132","author":"Wally","year":"2012","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.repc.2019.03.008_bib0665","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00424-018-2173-5","article-title":"Gene therapy strategies in the treatment of hypertrophic cardiomyopathy","volume":"471","author":"Prondzynski","year":"2019","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.repc.2019.03.008_bib0645","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/mtna.2013.31","article-title":"Repair of Mybpc3 mRNA by 5\u2032\u2010trans\u2010splicing in a Mouse Model of Hypertrophic Cardiomyopathy","volume":"2","author":"Mearini","year":"2013","journal-title":"Mol Ther Nucleic Acids."},{"key":"10.1016\/j.repc.2019.03.008_bib0650","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele\u2010specific Silencing of Mutant Myh6 Allele in Mice Suppresses Hypertrophic Cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.repc.2019.03.008_bib0660","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255120300299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255120300299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:09Z","timestamp":1760108889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255120300299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0870255120300299"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2019.03.008","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novas perspetivas no tratamento farmacol\u00f3gico da miocardiopatia hipertr\u00f3fica","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}